This year, the World Pharma Pricing and Market Access (PPMA) 2018 conference opened with some friendly and honest words from Sir Andrew Dillon, Chief Executive of the National Institute for Health and Care Excellence (NICE).
The phrase ‘inconsistent ambitions’ was used in relation to the current work of NICE, NHS England, patient organisations and the pharmaceutical industry, with the respect that organisations are often working towards antagonistic objectives. However, there was one familiar phrase that rang true across all parties, value. In a world of fixed and, some would argue, diminishing (per capita) resources, the ability to increase value and understand risk is critical on the journey to improving healthcare.
In order to achieve what the true value is we must recognise health systems constraints, maximise the opportunities within the system and take advantage of the scientific evidence available… doing all of these as early as possible.
The conference was cleverly built around 5 key themes, my focus for the day – rare diseases and the digital space:
- Rare Diseases
- Pricing & Modelling
- Novel Therapeutics
For more information about how you might incorporate these themes into your access strategy, why not get in touch?
Phil Drew is a Market Access Consultant at OPEN Access Consulting, a market access consulting and communications agency. For more information, please get in touch at PhilipDrew@openaccessconsulting.com